Amarin Corporation Loss Form

Company: Amarin Corporation

Ticker: (NASDAQGM) AMRN

Deadline

Passed

Lead Plaintiff Deadline: April 23, 2019

Never Miss Another Deadline

Choose your preferred way to stay informed of new case launches and settlement deadlines.

Scan the QR code or click the button to join.

Join on WhatsApp

Get Updates by Email

Subscribe for email notifications.

Full Name

No spam, opt-out anytime, alert list is free.

Allegations

(1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.